Posted by Michael Wonder on 17 Dec 2019
Salarius Pharmaceuticals receives FDA fast track designation for lead drug candidate, seclidemstat, in relapsed or refractory Ewing sarcoma
16 December 2019 - Phase 1/2 clinical study now underway; Salarius targeting key safety and efficacy data milestones in 2020.
Salarius Pharmaceuticals announced today that its lead investigational drug candidate, Seclidemstat, has been granted fast track designation by the U.S. FDA for the treatment of patients with Ewing sarcoma who have relapsed or are refractory to standard-of-care therapy.
Seclidemstat, a potent reversible LSD1 inhibitor, is the subject of an ongoing Phase 1/2 clinical study in Ewing sarcoma.
